BIO-PATH HOLDINGS INC (BPTH) Stock News

NASDAQ:BPTH - US09057N4097 - Common Stock

0.21 USD

-0.42 (-66.84%)

Last: 2/18/2025, 8:00:01 PM

0.2142 USD

+0 (+2%)

After Hours: 2/18/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BPTH Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Virtual Investor Conferences - Mentions: NIKA TIVC ADIA STSS ...

Life Sciences Investor Forum: Now Available for Online Viewing

3 months ago - By: Virtual Investor Conferences - Mentions: NIKA TIVC ADIA STSS ...

Life Sciences Investor Forum Agenda Announced for June 11th-12th

5 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports Full Year 2024 Financial Results

3 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

3 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

3 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides Clinical and Operational Update

3 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides Clinical and Operational Update

3 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

3 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

4 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

4 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

5 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Reports Full Year 2024 Financial Results

5 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

5 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

6 months ago - By: Benzinga - Mentions: HCTI PRFX PTPI KWE ...

US Stocks Mixed; NY State Business Activity Rises In February

6 months ago - By: Benzinga - Mentions: CAMP MBRX HCTI GLYC ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

6 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Expands Global Patent Portfolio

6 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Expands Global Patent Portfolio

6 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides Key Clinical Updates

6 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides Key Clinical Updates

6 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

6 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

8 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides 2025 Clinical and Operational Update

8 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Provides 2025 Clinical and Operational Update

8 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

8 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

9 months ago - By: Bio-Path Holdings, Inc.

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients